- Investing.com
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
Future Growth Drivers | Explore RadNet's potential for margin expansion through operational efficiencies, AI integration, and the acceleration of its DeepHealth segment |
Market Valuation | Analyst targets range from $71 to $92 per share, reflecting optimism about RadNet's growth prospects and market positioning in healthcare technology |
Financial Resilience | Despite weather-related challenges, RadNet demonstrates robust performance with revenue beats and raised guidance, showcasing operational adaptability |
Imaging Innovato | RadNet's strategic acquisition of iCAD for $103 million positions the company at the forefront of AI-driven diagnostic imaging technology |
Metrics to compare | RDNT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDNTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −438.3x | 22.5x | −0.6x | |
PEG Ratio | 2.72 | 0.14 | 0.00 | |
Price / Book | 5.3x | 2.6x | 2.6x | |
Price / LTM Sales | 2.8x | 1.2x | 3.4x | |
Upside (Analyst Target) | 29.9% | 24.1% | 42.0% | |
Fair Value Upside | Unlock | 7.4% | 5.8% | Unlock |